Salam Abou Safrah

Dr. Salam Abou Safrah


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2024 in Pharmacy
Verified
Journal Article
Open access
PDF file
DADania Alkhiyami
Dania Alkhiyami
SSSalam Abou Safrah
Salam Abou Safrah
ASAhsan Sethi
Ahsan Sethi
MHMuhammad Abdul Hadi
Muhammad Abdul Hadi
(1) Background: This scoping review aims to explore the literature on feedback for pharmacy students during experiential learning, with a focus on identifying the modes of delivery of feedback and the perceived impact of feedback on student learning outcomes. (2) Methods: The scoping review was conducted in accordance with the Joanna Briggs Institute (JBI) methodology and reported following the Preferred Reporting Items for Systematic Reviews Extension for Scoping Reviews (PRISMA-ScR) guidelines. PubMed, Web of Science, Embase, EBSCO, ERIC, and ProQuest Central were searched electronically from their inception until the end of February 2023 using a combination of keywords and MeSH terms related to feedback, pharmacy education, and student learning outcomes. Data were synthesized narratively. (3) Results: This review included 13 studies published between 2008 and 2022. Almost half of the included studies were conducted in the USA (n = 6, 46%) and reported the perspective of undergraduate pharmacy students (n = 6, 46%). Verbal feedback was the most common mode of feedback delivery (n = 6, 46%). The enablers of effective feedback included timely feedback (n = 6, 46%), feedback provided in a goal-oriented and objective manner (n = 5, 40%), and student-specific feedback (n = 4, 30%). On the other hand, the most common impediments to feedback efficacy were providing extremely positive feedback and lack of constructive criticism. (4) Conclusions: Our findings highlight the importance of feedback model implementation in pharmacy education and preceptor training programs to ensure effective and quality feedback to pharmacy students.

4 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MDMohammad Danjuma
Mohammad Danjuma
LNLina Naseralallah
Lina Naseralallah
MKMohamad Khatib
Mohamad Khatib
AAAzhar Alkhulaifi
Azhar Alkhulaifi
BABodoor Aboujabal
Bodoor Aboujabal
TCTawanda Chivese
Tawanda Chivese
Despite its pivotal role in drug metabolism, the exact consequences of rising medica-tions count from various therapeutic drug classes on mortality outcomes amongst patients with chronic liver disease remains unexplored. In this study, we investigated the effect of different polypharmacy phenotypes on clinical outcomes including the length of hospitalization, the need for intensive care admission, and mortality in patients with chronic liver disease (CLD). Methods: This retrospective cohort study examined the impact of various polypharmacy phenotypes on clinical outcomes of patients receiving care at tertiary care centres within the Weill Cornell Medi-cine-affiliated Hamad Medical Corporation, Doha Qatar diagnosed with CLD be-tween October 2018 to August 2021. Primary outcomes include all-cause mortality, length of hospitalization, and need for intensive care unit admission. Multivariable regression models were used to assess the associations between the number of liv-er-related and non-liver-related polypharmacy and these clinical outcomes. Results: In this retrospective cohort study, 3331 participants with a median age of 50 years (interquartile range [IQR] 40–63) were included, of which 71.0% (n = 2 366) were males. The total duration of follow-up for the whole cohort was 42 772.6 per-son-days. The median length of stay (LOS) was 5.0 (0.5, 13.6) days, with 762 (22.9%) deaths among those hospitalized. About 46.2% of the study participants were on guideline-directed therapy CLD drugs. Patients with polypharmacy inclusive of liver-related drugs had a higher survival over time compared to the group without polypharmacy (log-rank p< 0.001). Each additional CLD drug is associated with a 51% reduction in mortality risk (hazard ratio [HR] 0.49, 95% CI 0.38–0.62). Conclusion: In a hospitalized cohort of patients with CLD, polypharmacy comprising of medications specific for CLD or its complications was associated with reduced all-cause mortality. However, the role of non-liver-related medications in this context remains unclear, and it is uncertain how the primary cause of liver disease could have potentially impacted these outcomes. Further studies exploring these factors are needed to better inform clinical decision-making regarding polypharmacy management in this patient population